NASDAQ:GENEGenetic Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genetic Technologies Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.04 0.00 (0.00 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$1.99Now: $2.04▼$2.1550-Day Range$1.60MA: $2.07▼$2.5252-Week Range$1.41Now: $2.04▼$5.36Volume1.16 million shsAverage Volume1.21 million shsMarket Capitalization$17.38 millionP/E RatioN/ADividend YieldN/ABeta2.58 ProfileAdvanced ChartCompetitorsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Genetic Technologies. Previous Next 1.9 Community Rank Outperform VotesGenetic Technologies has received 159 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGenetic Technologies has received 255 “underperform” votes. (Add your “underperform” vote.)Community SentimentGenetic Technologies has received 61.59% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Genetic Technologies and other stocks. Vote “Outperform” if you believe GENE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GENE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGenetic Technologies does not currently pay a dividend.Dividend GrowthGenetic Technologies does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genetic Technologies insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 1.94% of the stock of Genetic Technologies is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioGenetic Technologies has a P/B Ratio of 7.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GENE Previous Symbol CUSIPN/A CIK1166272 Webwww.gtgcorporate.com Phone011-61-3-8412-7000Debt Debt-to-Equity Ratio0.05 Current Ratio2.95 Quick Ratio2.90Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20,000.00 Price / Sales869.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book7.85Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares8,520,000Market Cap$17.38 million Next Earnings DateN/A OptionableOptionable NASDAQ:GENE Rates by TradingView Receive GENE News and Ratings via Email Sign-up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter. Genetic Technologies (NASDAQ:GENE) Frequently Asked Questions How has Genetic Technologies' stock been impacted by COVID-19 (Coronavirus)? Genetic Technologies' stock was trading at $2.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GENE stock has decreased by 13.6% and is now trading at $2.04. View which stocks have been most impacted by Coronavirus. Has Genetic Technologies been receiving favorable news coverage? Media headlines about GENE stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Genetic Technologies earned a coverage optimism score of -2.6 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutGenetic Technologies. Who are some of Genetic Technologies' key competitors? Some companies that are related to Genetic Technologies include INmune Bio (INMB), Idera Pharmaceuticals (IDRA), Microbot Medical (MBOT), Allena Pharmaceuticals (ALNA), Polarityte (PTE), Acorda Therapeutics (ACOR), aTyr Pharma (LIFE), Pharmacyte Biotech (PMCB), Curis (CRIS), Creative Realities (CRDF), BioCardia (BCDA), TrovaGene (TROV), Titan Pharmaceuticals (TTNP), Entera Bio (ENTX) and Vitro Diagnostics (VODG). View all competitors. What other stocks do shareholders of Genetic Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genetic Technologies investors own include NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Vascular Biogenics (VBLT), Caladrius Biosciences (CLBS), Achillion Pharmaceuticals (ACHN), Cyclacel Pharmaceuticals (CYCC), Heat Biologics (HTBX), Opko Health (OPK) and Plug Power (PLUG). Who are Genetic Technologies' key executives? Genetic Technologies' management team includes the following people: Dr. Paul Alexander Kasian Ph.D., Exec. Chairman & CEO (Age 62)Dr. Jerzy Muchnicki, Exec. Director & Bus. Devel. DirectorMr. Paul Keith Mathieson Viney B. Bus, FCPA, FGIA, FCI, COO, CFO & Company Sec. What is Genetic Technologies' stock symbol? Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE." How do I buy shares of Genetic Technologies? Shares of GENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Genetic Technologies' stock price today? One share of GENE stock can currently be purchased for approximately $2.04. How big of a company is Genetic Technologies? Genetic Technologies has a market capitalization of $17.38 million and generates $20,000.00 in revenue each year. What is Genetic Technologies' official website? The official website for Genetic Technologies is www.gtgcorporate.com. How can I contact Genetic Technologies? Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The biotechnology company can be reached via phone at 011-61-3-8412-7000 or via email at [email protected] This page was last updated on 6/1/2020 by MarketBeat.com Staff
